MONSENSO A/S Company announcement no. 04-2024
Monsenso’s annual report for 2023 was approved by the Board of Directors today.
Performance highlights
- The total revenue increased by 55% to
DKK 9,624k (2022:DKK 6,213k ). -
EBITDA was
DKK -1,395k (2022: -3,997k). -
Cash flows from operating activities was now positive
DKK 2,552k (2022:DKK -3,390k ). -
The total equity as of
December 31, 2023 amounted toDKK 10,873k (2022:DKK 14,755k ). -
Total cash and cash equivalents as of
December 31, 2023 amounted toDKK 1,812k (2022 DKK 572k ).
Business developmentIncrease in revenue due to new sales and good progress on project portfolio.
- Improvement in EBITDA and profit due to increase in revenue.
- New, significant project customer and project wins in the pharmaceutical and health care markets.
- New innovation and research projects with leading project consortia successfully kicked off and progressing well.
- Impressive enhancements of the digital health platform.
- New evidence and research results published from the continuous innovation and research engagements.
CEO
2023 was a good and busy year for Monsenso.
We believe the markets for digital support of mental illness, chronic disorders and for real-world data collection in studies remain very attractive. The markets are expected to grow at a rapid pace in the coming years. Due to the aging population and the increasing burden of mental illness, the European health systems are under tremendous pressure to find scalable, new data-driven solutions to treat more people at home and to deliver good services with fewer resources.
With the increased engagement in both customer and innovation projects in the past year, the continuous flow of new research results, and the impressive progress we have made with our platform enhancements, we are well-positioned to empower more healthcare organisations and pharmaceuticals provide better interventions to more patients.
Outlook for 2024
For 2024, we expect revenue to be
Uncertainties and other financial information for 2023 are included in notes 2 and 3 of the financial statement.
Key figures |
|
|
(' | 2023 | 2022 |
Revenue | 9,624 | 6,213 |
EBITDA | (1,395) | (3,997) |
Profit (loss) for the year | (5,357) | (7,854) |
|
|
|
Cash flows from operating activities | 2,552 | (3,390) |
Total assets, end of year | 18,787 | 18,872 |
Equity, end of year | 10,873 | 14,755 |
|
|
|
Net profit per share (DKK) | (0.19) | (0.32) |
End-of-year, number of employees (FTE) | 12 | 11 |
CEO
Disclaimer
This report contains forward-looking statements which are based on the current expectations of the management. All statements regarding the future are subject to inherent risks and uncertainties, and many factors can lead to actual results and developments deviating substantially from what has been expressed or implied in such statements.
Any inquiries regarding this notice should be directed to:
Monsenso
CEO
Thomas Lethenborg
Tel +45 21 29 88 27
E-mail: lethenborg@monsenso.com
Chairman of the board
Tel +45 51 99 66 00
E-mail: Petermorcheriksen@outlook.com
Certified Adviser
Norden CEF A/S
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioral data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavors to deliver solutions that fit into the lives of patients and health care professionals. To learn more visit www.monsenso.com
Attachments
- Download announcement as PDF.pdf
- 2023 Annual Report.v3.pdf
© Ritzau Denmark, source
